Christopher Sowden MBiochem
London, England, United Kingdom
4K followers
500+ connections
About
Director at Walker Cole International
Walker Cole International offer Executive…
Activity
-
Reflections from CPHI - It was great to catch up with everyone over the week in Frankfurt. One of the repeated topics of discussion was transferring…
Reflections from CPHI - It was great to catch up with everyone over the week in Frankfurt. One of the repeated topics of discussion was transferring…
Liked by Christopher Sowden MBiochem
-
Rezon Bio CDMO launch party this evening with the Walker Cole International team at CPHI. #CDMOexcellence #lifesciences #pharmajobs
Rezon Bio CDMO launch party this evening with the Walker Cole International team at CPHI. #CDMOexcellence #lifesciences #pharmajobs
Shared by Christopher Sowden MBiochem
-
OXB bought an old bluebird bio manufacturing site in North Carolina. Here’s why it was such a steal!. OXB (formally Oxford Biomedica) has been on a…
OXB bought an old bluebird bio manufacturing site in North Carolina. Here’s why it was such a steal!. OXB (formally Oxford Biomedica) has been on a…
Liked by Christopher Sowden MBiochem
Experience
-
-
-
-
-
-
-
-
-
Education
-
University of Oxford
2.1
-
Activities and Societies: Christ Church College 2012-2016 Member of 1st XV Rugby team
-
-
-
-
-
-
Volunteer Experience
-
Ed's summer food tour team member
Catered
- 3 months
Children
Prepared and distributed over 200 lunches daily to disadvantaged children in the Plymouth area.
Spoke to parents, hearing how difficult they find it to make ends meet during summer months, used
to feedback to local government who are planning to publicly fund a similar scheme in
future school holidays.
Publications
-
Impact of Drugs on hydration of outer membrane leaflet lipids.
-
Masters Dissertation conducted in McLain Group, Department of Biochemistry, University of Oxford
Languages
-
English
Native or bilingual proficiency
More activity by Christopher
-
Over a month to go until CPHI Frankfurt 2025! 🌐 With increased geographical expansions into Europe, the US and emerging markets I see more and…
Over a month to go until CPHI Frankfurt 2025! 🌐 With increased geographical expansions into Europe, the US and emerging markets I see more and…
Liked by Christopher Sowden MBiochem
-
●●● 𝐏𝐡𝐚𝐫𝐦𝐚 𝐆𝐢𝐚𝐧𝐭𝐬 𝐐𝟏 𝟐𝟎𝟐𝟓: 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 & 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 ●●● For more follow…
●●● 𝐏𝐡𝐚𝐫𝐦𝐚 𝐆𝐢𝐚𝐧𝐭𝐬 𝐐𝟏 𝟐𝟎𝟐𝟓: 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 & 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 ●●● For more follow…
Liked by Christopher Sowden MBiochem
-
"I hate contractors, they're too expensive and rarely deliver value for money" "Consultants are integral to my team, I can increase and decrease…
"I hate contractors, they're too expensive and rarely deliver value for money" "Consultants are integral to my team, I can increase and decrease…
Liked by Christopher Sowden MBiochem
-
‼️ New Qualified Person Opportunity - London ‼️ I'm partnered with a dynamic, London-based global pharmaceutical business on an exciting…
‼️ New Qualified Person Opportunity - London ‼️ I'm partnered with a dynamic, London-based global pharmaceutical business on an exciting…
Liked by Christopher Sowden MBiochem
-
🎓 2025 Graduates – Still searching for the right opportunity? Join our Graduate Management Trainee Programme at Walker Cole International – a…
🎓 2025 Graduates – Still searching for the right opportunity? Join our Graduate Management Trainee Programme at Walker Cole International – a…
Liked by Christopher Sowden MBiochem
Other similar profiles
Explore more posts
-
James Carpenter
Something I hear from clients all the time is: “We only want candidates from a Pharma or Biotech background — no CROs, no Research.” I get the concern — especially in stats, where trial design experience is crucial. Many CROs are handed trial designs and SAPs, which can raise doubts for hiring managers. But that’s not always the case. In FSP models (and even in certain CRO setups), statisticians do get involved in design work and take on responsibilities just as broad as their Pharma counterparts. So simply ruling out CRO candidates because of an assumption feels short-sighted. You’re potentially dismissing professionals who’ve handled multiple trials across different phases, with varied clients — building adaptability and technical depth along the way. Some of the strongest placements I’ve made came from CRO backgrounds. They brought drive, flexibility, and fresh perspectives into Pharma/Biotech teams. Maybe I’m wrong — but I can’t help thinking the industry is missing out by painting all CRO experience with the same brush. JCR Pharma Jessica Smith Mathy Bekele Rachel Reidy
6 Comments -
Robert Anderson
🌍 Huge news from Glasgow's deep-tech frontier! After their exciting recent announcement of their relocation to Glasgow's Health Innovation Hub, University of Glasgow spinout Chemify Limited have today announced that they have raised over $50 million in their Series B funding round! 💵 Chemify and their 160-strong team are looking to use the funding to become a world leader in digital chemistry. The company's innovative AI-driven molecule creation platform has attracted investment from across the globe as the company continues to develop and explore further potential applications! 🚀 Great to see a Glasgow-based company do so well AND keep their hubs right in the heart of the city. 💓 #SRGScotland #DigitalChemistry #Funding #Innovation
1 Comment -
Jessica Taylor
🔬 Cell & Gene Therapy Momentum in the UK/EU – July 2025 Update 🚀 The UK and Europe are making big moves in cell and gene therapy this month: ✅ UK approves needle-free adrenaline spray The MHRA has approved Eurneffy, the first needle-free treatment for anaphylaxis – a breakthrough for accessibility and ease of use. ✅ First patient dosed with Hemgenix in Germany Europe’s first gene therapy for haemophilia B has begun dosing – a major milestone for long-term treatment. ✅ New EU approvals • Vyjuvek: a topical gene therapy for a rare skin disorder • Duvyzat: approved for Duchenne muscular dystrophy ✅ UK’s plan to boost clinical trials New Life Sciences Sector Plan aims to reduce approval times and strengthen the UK’s position as a global leader in advanced therapies. ✅ Gene-editing therapy rollout The NHS continues to expand access to Casgevy for sickle cell and thalassemia – with more patients set to benefit across England. 📣 This progress shows strong collaboration between regulators, the NHS, and biotech innovators. Exciting to see real-world impact grow across the region. 👉 What do you think is the biggest opportunity or challenge ahead for CGT in Europe? #CellTherapy #GeneTherapy #LifeSciences #UKBiotech #EUTherapies #HealthInnovation #ATMP
1 Comment
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More